CardiovascularDiseases pertain to the blood vessel and heart conditions that can affect the heart valve, cardiac muscle with the circulation system that monitors the blood flow and distribution and the cardiac electrical system which controls the heart rhythm and rate. These complex systems are taken care of by the cardiovascular therapy device market owing to the increasing number of global population being affected by the above mentioned diseases. The cardiovascular therapy market is expected to grow in the forecast period owing to introduction of improved technologies and devices that provide solutions for Cardio vascular diseases.
Growth
in the global cardiovascular therapy market is attributed to factors owing to
increasing worldwide prevalence of chronic CVDs and a higher percentage of
aging population. Improvements in treatment capabilities in developing markets
owing to technological advancements and innovation is expected to have a
positive impact on the demand for cardiovascular thereupatic devices in the
medical and healthcare sector. Technological advent with respect to therapeutic
devices includes development of extended product life, smaller devices, and
surgical improvements. Increase in demand is also driven by increased risk factors
(diabetes, smoking, obesity, and hypertension) among people
Request Sample Copy of This Market Research @
https://www.millioninsights.com/industry-reports/cardiovascular-therapy-market/request-sample
Key
application of in cardiovascular therapy is the hybrid operation rooms market
that emphasizes on minimal invasive surgeries. Therefore, Global cardiovascular
therapy market is expected to witness a growth owing to increasing demand for
minimally invasive surgeries. However, high costs for treatment and safety
concerns are major challenges before the market. Cardiovascular therapy
comprises of Anti-hypertensives, anticoagulants, anti-arrhythmic,
Antithrombotics and Antidyslipidemics. Global cardiovascular market had a sale
of $170bn in 2010 and is expected to have a positive growth in the forecast
period. With a share of 40% of the total market, the US continued to be the
market leader in this segment. Although there has been a decline in the sales
of cardiovascular therapy market due to saturation of key drug categories and
an increased generic presence, the US witnessed a steady growth in the market
since 2009 and is expected to continue the same trend.
Antihypertensives
remained the largest drug class in the past few years with global sales of over
$37.6bn and an overall market share of over 22%. Angiotensin receptor blockers
(ARBs) is expected to remain the most prescribed therapeutic class within
antihypertensives driven by key brands such as Cozaar, Diovan, and Avapro.
Novartis’s Diovan is the market leader with $3.6bn in sales and the second
largest being Benicar with sales of $2.9bn. The anticoagulants segment is
expected to witness significant activity over the forecast period owing to
introduction of new drugs such as BoehringerPradaxa/Rendix, Ingelheim's,
Bayer-Schering/J&J's, BMS/Pfizer's apixaban, Xarelto and Eli
Lilly/Daiichi's Effient which are subjected to intensive R&D activities.
Since most of the factor Xa inhibitors are in oral form, they are expected to
cater to a wider market.
Crestor
is expected to witness a steady growth in the market owing to positive trial
results that has the capability to strengthen its market position. The positive
trial data is likely to result in higher number of recommendations for
cholesterol treatment and capture more number of patients with cardiovascular
disorders GlaxoSmithKline's (GSK) is expected to have the highest growth among
leading players owing to the acquisition of Reliant Pharma. Addition of new
drugs such as Lovaza in GSKs portfolio is a key factor that can drive the
growth in this segment In 2010, Antithrombotics recorded a sale of over
$18.7bn and a market share of over 11%. Antithrombitics are forecasted to
witness a strong growth in the next seven years owing to increase in the
commercialization of recently approved products such as Xarelto, Pradaxa and
launch of Pfizer/BMS’s apixabanBetter bleeding profile and superior effectiveness
of Brilinta (ticagrelor) over Plavix make it major antithrombotic drug that
could be a key player in acute coronary syndrome (ACS).
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/cardiovascular-therapy-market
A
large segment of atherosclerosis patients who do not respond to Plavix can be
administered by Brilinta which has a potential therapeutic advantage in
atherosclerosis Moreover, its use could be initially confined to acute coronary
syndrome (ACS) with no patient monitoring anticipated for postmarketing
surveillanceor respiratory or cardiac function requirements. The
anti-arrhythmic market is expected to remain a small opportunity as this drug
therapy has substantial limitations. New therapeutic standards and benchmarks
are expected to be set by Multaq from Sanofi-Aventis owing to its first-line
treatment of chronic atrial fibrillation.
Future
technologies that are expected to have a positive impact on the market are
third generation VADs in cardiac surgery that have the property to easily be
implanted, Interventional cardiology that employs innovative therapies such as
stem cell therapies and bioabsorbable stents, electrophysiology that focuses on
developing implants that does not use lead and advanced endovascular therapy.
Key regional segments include Europe, North America, Asia Pacific, Latin
Americaand MEAIn 2014, Asia Pacific held the majority of share in global
cardiovascular therapy market. Key factors contributing to its large share
include prevalence of the target diseases such as hernia and congenital heart
diseases. North America is expected to be the fastest growing regions over the
forecast period. Health awareness among consumers and presence of improved
healthcare infrastructure and pertaining to the availability of new products is
expected to increase the use of cardiovascular over the forecast period.
Read more insights on @
https://latestmarkettrends.news.blog
Get in touch
At Million Insights, we work with the aim to reach the highest levels
of customer satisfaction. Our representatives strive to understand diverse
client requirements and cater to the same with the most innovative and
functional solutions.
Contact Person:
Ryan Manuel
Research Support Specialist, USA
Email: ryan@millioninsights.com
Comments
Post a Comment